The effect of cyclosporin administered during a third-party blood transfusion protocol on humoral immune responses.
Antigen pre-treatment in animals undoubtedly prolongs graft survival. In man, however, routine pre-transplantation blood transfusions have recently become controversial, principally because of the adverse effect of transfusion-induced sensitisation on graft survival rates. We have monitored the effect of cyclosporin administered during a planned programme of third-party blood transfusions on the development of both cytotoxic and anti-idiotypic antibodies. A total of 24 patients were recruited to the study; ten received cyclosporin with blood transfusions (BT) (group 1), 14 received BT alone (group 2). Anti-HLA antibodies developed in 3 of 9 patients in group 1 and 8 of 12 patients in group 2 (P less than 0.05). Anti-idiotypic antibody activity was detectable in 9 of 9 patients in group 1 and 7 of 12 patients in group 2 (P less than 0.006). The mechanism by which cyclosporin can prevent an anti-HLA antibody response and promote an anti-idiotypic response is unclear.
Jones
M C
MC
Department of Medicine and Therapeutics, Foresterhill, Aberdeen, UK.
Stewart
K N
KN
Propper
D J
DJ
Catto
G R
GR
Power
D A
DA
D000888:Antibodies, Anti-Idiotypic / Q000032:analysis; D000917:Antibody Formation / Q000187:drug effects*; D001803:Blood Transfusion; D003165:Complement System Proteins / Q000276:immunology; D003524:Cyclosporins / Q000494:pharmacology*; D003602:Cytotoxicity, Immunologic; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D016030:Kidney Transplantation; D008297:Male
D000888:Antibodies, Anti-Idiotypic; D003524:Cyclosporins; D006680:HLA Antigens; D007074:Immunoglobulin G; D003165:Complement System Proteins